{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:08:45Z","timestamp":1784848125301,"version":"3.55.0"},"reference-count":41,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T00:00:00Z","timestamp":1488153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Clonidine is used for sedation in the paediatric intensive care unit. Extracorporeal membrane oxygenation (ECMO) provides temporary support if respiratory and cardiac function is threatened. ECMO influences the pharmacokinetics of drugs. Clonidine during paediatric ECMO cannot be effectively titrated as PK data are lacking. The aim of this study is to describe clonidine PK in a particular ECMO system and propose dosing guidelines for children on this particular ECMO circuit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All children below the age of 18 years who received clonidine during ECMO were eligible. The pharmacokinetic analysis was conducted by nonlinear mixed effect modelling, which enables to establish the separate influences of determinants on drug blood level and to provide individualized dosing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010two patients, median age 1\u00a0month (IQR 6.4) and weight at inclusion 4\u00a0kg (IQR 3.1) were included of whom 90% in addition to ECMO received pre\u2010emptive continuous venovenous hemofiltration to optimize fluid balance. The clonidine clearance rate was two\u2010fold that measured in patients not on ECMO. Clearance increased steeply with postnatal age: at days 6, 8 and 10, respectively 30%, 50% and 70% of the adult clearance rate was reached. The use of diuretics was associated with a lower clearance. The volume of distribution increased by 55% during ECMO support.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings suggest that a higher dose of clonidine may be needed during ECMO. The PK parameters on ECMO and the dosing guidelines proposed hold the potential to improve sedation practices on ECMO but need to be repeated with different ECMO systems.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13235","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T14:27:52Z","timestamp":1484231272000},"page":"1227-1239","source":"Crossref","is-referenced-by-count":22,"title":["Population pharmacokinetics of intravenous clonidine for sedation during paediatric extracorporeal membrane oxygenation and continuous venovenous hemofiltration"],"prefix":"10.1111","volume":"83","author":[{"given":"Niina","family":"Kleiber","sequence":"first","affiliation":[{"name":"Intensive Care and Department of Pediatric Surgery Erasmus MC\u2013Sophia Children's Hospital  P.O. Box 2060 3000 CB Rotterdam The Netherlands"},{"name":"Department of Pediatrics CHU Sainte\u2010Justine  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A. A.","family":"Math\u00f4t","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy Academic Medical Centre  Amsterdam, Meibergdreef 9 1105 AZ Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice J.","family":"Ahsman","sequence":"additional","affiliation":[{"name":"Intensive Care and Department of Pediatric Surgery Erasmus MC\u2013Sophia Children's Hospital  P.O. Box 2060 3000 CB Rotterdam The Netherlands"},{"name":"LAP&amp;P Consultants BV  Archimedesweg 3 1 2333 CM Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno D.","family":"Wildschut","sequence":"additional","affiliation":[{"name":"Intensive Care and Department of Pediatric Surgery Erasmus MC\u2013Sophia Children's Hospital  P.O. Box 2060 3000 CB Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Tibboel","sequence":"additional","affiliation":[{"name":"Intensive Care and Department of Pediatric Surgery Erasmus MC\u2013Sophia Children's Hospital  P.O. Box 2060 3000 CB Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia N.","family":"de Wildt","sequence":"additional","affiliation":[{"name":"Intensive Care and Department of Pediatric Surgery Erasmus MC\u2013Sophia Children's Hospital  P.O. Box 2060 3000 CB Rotterdam The Netherlands"},{"name":"Department of Pharmacology and Toxicology Radboud University  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,27]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Registry TELSOE. ECLS Registry Report International Summary 20152015. Available from:https:\/\/www.elso.org."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc7771"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920012800840383"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000000151"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2010.03460.x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1213\/01.ane.0000255729.96438.b0"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0885066610396815"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2253-12-29"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-303721"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.PCC.0000149318.40279.1A"},{"key":"e_1_2_10_12_1","unstructured":"Team RDC.R: a language and environment for statistical computing. In: R Foundation for Statistical Computing Vienna."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2011.02.014"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2007.12.002"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2007.02251.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010370587"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2010.03397.x"},{"key":"e_1_2_10_21_1","volume-title":"Determinants of pharmacokinetic variability during extracorporeal membrane oxygenation","author":"Ahsman M","year":"2010"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01284.x"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-8180(05)80018-2"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265932"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-010-2041-z"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc11679"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0891-z"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-009-2862-1"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt1068"},{"key":"e_1_2_10_30_1","unstructured":"IngelheimB.Product Monograph: Catapres (clonidine hydrochloride).2012."},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.83.2_Supplement.386"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2011.577739"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.021873"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1396"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(96)80133-8"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201510-2114OC"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-014-3221-z"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/11319970-000000000-00000"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/1749-8090-8-186"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta18710"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/86.1.5"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeu258"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13235","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T08:54:21Z","timestamp":1696323261000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,27]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/bcp.13235"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13235","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,27]]}}}